Professor David Nisbet to lead MedTech platform
Dave is a Professor of Translational Biomedical Engineering who is jointly appointed between FEIT and the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne. As the Director of the Graeme Clark Institute (GCI) and the head of the Laboratory of Advanced Biomaterials, he brings a wealth of experience and knowledge to the role. The alignment of GCI and the MedTech platform will leverage high quality facilities and expertise in advanced biomechanics, electroceuticals, neuroimaging, personalised implants, biomaterials, regenerative medicine and medical informatics.
My vision is to bring engineering to the global health community. I am passionate about leverage this opportunity to make the University of Melbourne and the MedTech platform a world leading translational activity. I believe it is not enough to have new ideas and technologies, but that we need to translate these to better outcomes for people.Professor David Nisbet.
Dave is interested in developing novel biomaterials, and particularly about seeing the biomaterials developed for clinical applications. His research groups consist of a team of engineers, chemists, and biologists, all working together to create novel materials to help combat injury and disease.
The platform brings together expertise from engineering, technology, medicine and science to develop tools to improve community health and individual patient outcomes. In close collaboration with industry partners, it provides valuable pathways to bring new technologies into real-world healthcare applications.
The MedTech platform will continue to target at current global health challenges including rising costs, inequality in access to health care, an increasing prevalence of chronic disease, and issues associated with the health system’s ‘one-size-fits all’ approach. It is critical to bring together clinicians, biomedical technologies and Big Data analysis, to delivery of next generation solutions in medicine.
We look forward to welcoming Dave to the platform as we continue to deliver innovative and impactful research that improves the long-term outcomes for patients and society. Dave takes over the position from David Grayden, who has led the platform for the past three years. We thank David Grayden for his leadership of the MedTech platform and for being a champion of industry facing MedTech research.